CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Adaptive Biotechnologies Corporation - ADPT CFD

2.43
12.04%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.04
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Adaptive Biotechnologies Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.74
Open* 2.75
1-Year Change* -64.92%
Day's Range* 2.41 - 2.75
52 wk Range 2.61-10.38
Average Volume (10 days) 1.50M
Average Volume (3 months) 32.33M
Market Cap 589.23M
P/E Ratio -100.00K
Shares Outstanding 144.77M
Revenue 179.69M
EPS -1.36
Dividend (Yield %) N/A
Beta 1.26
Next Earnings Date Feb 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 17, 2024 2.41 -0.31 -11.40% 2.72 2.76 2.41
Apr 16, 2024 2.74 -0.01 -0.36% 2.75 2.80 2.60
Apr 15, 2024 2.89 -0.07 -2.36% 2.96 3.09 2.86
Apr 12, 2024 3.01 0.49 19.44% 2.52 3.07 2.52
Apr 11, 2024 2.58 -0.07 -2.64% 2.65 2.66 2.51
Apr 10, 2024 2.64 -0.10 -3.65% 2.74 2.78 2.62
Apr 9, 2024 2.91 0.10 3.56% 2.81 3.09 2.81
Apr 8, 2024 2.81 0.22 8.49% 2.59 2.81 2.55
Apr 5, 2024 2.56 -0.13 -4.83% 2.69 2.69 2.54
Apr 4, 2024 2.69 0.00 0.00% 2.69 2.89 2.65
Apr 3, 2024 2.66 -0.23 -7.96% 2.89 2.91 2.64
Apr 2, 2024 2.95 -0.05 -1.67% 3.00 3.02 2.87
Apr 1, 2024 3.09 -0.14 -4.33% 3.23 3.24 3.03
Mar 28, 2024 3.18 0.25 8.53% 2.93 3.31 2.93
Mar 27, 2024 2.87 -0.05 -1.71% 2.92 2.92 2.73
Mar 26, 2024 2.85 -0.21 -6.86% 3.06 3.17 2.83
Mar 25, 2024 3.09 -0.07 -2.22% 3.16 3.26 3.07
Mar 22, 2024 3.22 -0.03 -0.92% 3.25 3.27 3.13
Mar 21, 2024 3.31 -0.04 -1.19% 3.35 3.50 3.29
Mar 20, 2024 3.36 0.15 4.67% 3.21 3.40 3.13

Adaptive Biotechnologies Corporation Events

Time (UTC) Country Event
Wednesday, May 1, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Adaptive Biotechnologies Corp Earnings Release
Q1 2024 Adaptive Biotechnologies Corp Earnings Release

Forecast

-

Previous

-
Friday, June 7, 2024

Time (UTC)

16:00

Country

US

Event

Adaptive Biotechnologies Corp Annual Shareholders Meeting
Adaptive Biotechnologies Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, July 31, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Adaptive Biotechnologies Corp Earnings Release
Q2 2024 Adaptive Biotechnologies Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 185.308 154.344 98.382 85.071 55.663
Revenue 185.308 154.344 98.382 85.071 55.663
Cost of Revenue, Total 57.909 49.301 22.53 22.274 19.668
Gross Profit 127.399 105.043 75.852 62.797 35.995
Total Operating Expense 385.494 363.31 251.199 163.462 105.419
Selling/General/Admin. Expenses, Total 183.23 169.967 110.894 68.785 44.895
Research & Development 122.717 142.343 116.072 70.705 39.157
Depreciation / Amortization 20.038 1.699 1.703 1.698 1.699
Unusual Expense (Income) 1.6 0 0
Operating Income -200.186 -208.966 -152.817 -78.391 -49.756
Interest Income (Expense), Net Non-Operating -0.182 1.668 6.59 9.785 3.309
Net Income Before Taxes -200.368 -207.298 -146.227 -68.606 -46.447
Net Income After Taxes -200.368 -207.298 -146.227 -68.606 -46.447
Net Income Before Extra. Items -200.191 -207.279 -146.227 -68.606 -46.447
Net Income -200.191 -207.279 -146.227 -68.606 -46.447
Total Adjustments to Net Income 0 0 -0.964 0.102
Income Available to Common Excl. Extra. Items -200.191 -207.279 -146.227 -69.57 -46.345
Income Available to Common Incl. Extra. Items -200.191 -207.279 -146.227 -69.57 -46.345
Diluted Net Income -200.191 -207.279 -146.227 -69.57 -46.345
Diluted Weighted Average Shares 142.516 140.355 131.216 125.238 118.474
Diluted EPS Excluding Extraordinary Items -1.40469 -1.47682 -1.1144 -0.5555 -0.39118
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -1.3905 -1.47682 -1.1144 -0.5555 -0.39118
Total Extraordinary Items 0
Minority Interest 0.177 0.019
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 48.926 37.647 55.198 47.83 43.66
Revenue 48.926 37.647 55.198 47.83 43.66
Cost of Revenue, Total 17.91 18.681 16.589 14.907 13.221
Gross Profit 31.016 18.966 38.609 32.923 30.439
Total Operating Expense 96.744 94.84 94.384 93.261 96.162
Selling/General/Admin. Expenses, Total 46.174 43.139 46.144 42.268 45.481
Research & Development 29.471 28.828 27.341 30.017 32.76
Depreciation / Amortization 3.189 4.192 4.31 6.069 4.7
Operating Income -47.818 -57.193 -39.186 -45.431 -52.502
Interest Income (Expense), Net Non-Operating 0.007 -0.507 -0.983 0.112 0.418
Net Income Before Taxes -47.811 -57.7 -40.169 -45.319 -52.084
Net Income After Taxes -47.811 -57.7 -40.169 -45.319 -52.084
Net Income Before Extra. Items -47.81 -57.699 -40.128 -45.281 -52.046
Net Income -47.81 -57.699 -40.128 -45.281 -52.046
Income Available to Common Excl. Extra. Items -47.81 -57.699 -40.128 -45.281 -52.046
Income Available to Common Incl. Extra. Items -47.81 -57.699 -40.128 -45.281 -52.046
Diluted Net Income -47.81 -57.699 -40.128 -45.281 -52.046
Diluted Weighted Average Shares 144.398 143.511 143.061 142.929 142.364
Diluted EPS Excluding Extraordinary Items -0.3311 -0.40205 -0.2805 -0.31681 -0.36559
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.3311 -0.40205 -0.2805 -0.31681 -0.36559
Minority Interest 0.001 0.001 0.041 0.038 0.038
Unusual Expense (Income) 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 562.146 402.748 726.914 612.69 180.718
Cash and Short Term Investments 498.196 353.061 688.269 576.866 165.018
Cash & Equivalents 90.03 139.065 123.436 96.576 55.03
Short Term Investments 408.166 213.996 564.833 480.29 109.988
Total Receivables, Net 40.057 17.409 10.047 12.676 4.807
Accounts Receivable - Trade, Net 40.057 17.409 10.047 12.676 4.807
Total Inventory 14.453 19.263 14.063 9.069 7.838
Prepaid Expenses 9.44 13.015 14.535 14.079 3.055
Total Assets 856.617 923.344 1116.41 912.302 332.688
Property/Plant/Equipment, Total - Net 164.21 172.94 139.042 60.355 19.125
Property/Plant/Equipment, Total - Gross 218.56 209.166 163.424 78.471 31.577
Accumulated Depreciation, Total -54.35 -36.226 -24.382 -18.116 -12.452
Goodwill, Net 118.972 118.972 118.972 118.972 118.972
Intangibles, Net 6.827 8.526 10.225 11.928 13.626
Long Term Investments 0 217.145 118.525 105.435 0
Other Long Term Assets, Total 4.462 3.013 2.736 2.922 0.247
Total Current Liabilities 109.788 113.807 105.197 78.313 22.8
Accounts Payable 8.084 3.307 3.237 4.453 1.793
Accrued Expenses 37.395 29.649 26.874 10.433 7.203
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 64.309 80.851 75.086 63.427 13.804
Total Liabilities 392.452 319.352 373.148 341.263 29.942
Total Long Term Debt 0 0 0 36.607 0.336
Long Term Debt 0 0.336
Other Liabilities, Total 282.731 205.435 267.951 226.343 6.806
Total Equity 464.165 603.992 743.266 571.039 302.746
Redeemable Preferred Stock 0 572.866
Preferred Stock - Non Redeemable, Net -12.008
Common Stock 0.014 0.014 0.014 0.012 0.001
Additional Paid-In Capital 1387.35 1324.01 1253.97 935.834 37.902
Retained Earnings (Accumulated Deficit) -919.082 -718.891 -511.612 -365.478 -295.908
Other Equity, Total -4.116 -1.137 0.893 0.671 -0.107
Total Liabilities & Shareholders’ Equity 856.617 923.344 1116.41 912.302 332.688
Total Common Shares Outstanding 143.105 141.394 137.647 125.238 118.474
Capital Lease Obligations 0 36.607
Minority Interest -0.067 0.11
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 435.237 476.809 501.333 562.146 564.38
Cash and Short Term Investments 371.132 417.23 440.695 498.196 508.079
Cash & Equivalents 88.713 109.24 94.612 90.03 217.552
Short Term Investments 282.419 307.99 346.083 408.166 290.527
Total Receivables, Net 31.211 31.545 30.972 40.057 26.549
Accounts Receivable - Trade, Net 31.211 31.545 30.972 40.057 26.549
Total Inventory 19.49 18.96 19.874 14.453 17.345
Prepaid Expenses 13.404 9.074 9.792 9.44 12.407
Total Assets 717.682 764.54 791.463 856.617 884.208
Property/Plant/Equipment, Total - Net 152.012 156.499 160.254 164.21 169.267
Goodwill, Net 118.972 118.972 118.972 118.972 118.972
Intangibles, Net 5.557 5.985 6.408 6.827 7.256
Long Term Investments 0 19.698
Other Long Term Assets, Total 5.904 6.275 4.496 4.462 4.635
Total Current Liabilities 93.298 95.335 90.101 109.788 104.018
Accounts Payable 4.483 9.163 6.333 8.084 4.163
Accrued Expenses 33.475 28.255 23.448 37.589 31.963
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 55.34 57.917 60.32 64.115 67.892
Total Liabilities 355.95 368.504 367.443 392.452 396.368
Total Long Term Debt 0 0 0 0 0
Minority Interest -0.095 -0.069 -0.068 -0.067 -0.026
Other Liabilities, Total 262.747 273.238 277.41 282.731 292.376
Total Equity 361.732 396.036 424.02 464.165 487.84
Common Stock 0.014 0.014 0.014 0.014 0.014
Additional Paid-In Capital 1436.86 1421.51 1402.69 1387.35 1372.75
Retained Earnings (Accumulated Deficit) -1074.89 -1024.59 -976.781 -919.082 -878.954
Other Equity, Total -0.25 -0.893 -1.905 -4.116 -5.971
Total Liabilities & Shareholders’ Equity 717.682 764.54 791.463 856.617 884.208
Total Common Shares Outstanding 144.773 144.645 144.28 143.105 142.987
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -200.368 -207.298 -146.227 -68.606 -46.447
Cash From Operating Activities -183.945 -192.727 -149.683 205.404 -32.259
Cash From Operating Activities 19.221 12.254 6.769 6.093 4.301
Amortization 1.699 1.699 1.703 1.698 1.699
Non-Cash Items 67.049 57.434 28.871 11.286 9.911
Changes in Working Capital -71.546 -56.816 -40.799 254.933 -1.723
Cash From Investing Activities 2.905 181.21 -117.044 -481.697 0.736
Capital Expenditures -16.349 -61.746 -18.803 -11.2 -6.318
Other Investing Cash Flow Items, Total 19.254 242.956 -98.241 -470.497 7.054
Cash From Financing Activities 132.265 27.146 293.587 319.916 1.248
Financing Cash Flow Items 124.375 0.429 -0.321 -4.989 -0.02
Issuance (Retirement) of Stock, Net 7.89 26.717 293.908 324.905 1.268
Net Change in Cash -48.775 15.629 26.86 43.623 -30.275
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -57.7 -200.368 -160.199 -114.88 -62.796
Cash From Operating Activities -59.152 -183.945 -153.926 -111.518 -64.453
Cash From Operating Activities 5.004 19.221 14.364 9.409 4.637
Amortization 0.419 1.699 1.27 0.842 0.419
Non-Cash Items 17.6 67.049 51.049 34.802 15.495
Changes in Working Capital -24.475 -71.546 -60.41 -41.691 -22.208
Cash From Investing Activities 62.979 2.905 100.449 42.434 37.688
Capital Expenditures -2.924 -16.349 -13.807 -8.375 -3.077
Other Investing Cash Flow Items, Total 65.903 19.254 114.256 50.809 40.765
Cash From Financing Activities 0.672 132.265 132.259 6.739 2.749
Financing Cash Flow Items 124.375 124.691 0 0
Issuance (Retirement) of Stock, Net 0.672 7.89 7.568 6.739 2.749
Net Change in Cash 4.499 -48.775 78.782 -62.345 -24.016
Cash Interest Paid 2.76

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Adaptive Biotechnologies Corporation Company profile

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Adaptive Biotechnologies Corp revenues increased 57% to $154.3M. Net loss increased 42% to $207.3M. Revenues reflect Sequencing revenue segment increase of 90% to $78.9M, Development revenue segment increase of 32% to $75.4M. Higher net loss reflects Research and development - Balancing increase of 19% to $128.3M (expense), General and administrative - Balancing increase of 47% to $59.7M (expense).

Industry: Bio Diagnostics & Testing

1165 Eastlake Ave E
SEATTLE
WASHINGTON 98109
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

2,969.17 Price
+0.150% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,376.65 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

US100

17,594.40 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.49 Price
-0.390% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading